Healthcare provider profile · identity verified

Daniel Maher, N.P.

Nurse Practitioner · CHICAGO, IL · NPI 1760431985

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	353	124
Amlodipine Besylate	Amlodipine Besylate	213	93
Levothyroxine Sodium	Levothyroxine Sodium	177	59
Losartan Potassium	Losartan Potassium	149	56
Gabapentin	Gabapentin	144	45
Lisinopril	Lisinopril	129	54
Pantoprazole Sodium	Pantoprazole Sodium	129	36
Metformin Hcl	Metformin Hcl	128	45
Sertraline Hcl	Sertraline Hcl	107	25
Tamsulosin Hcl	Tamsulosin Hcl	99	38
Fluticasone Propionate	Fluticasone Propionate	89	43
Carvedilol	Carvedilol	84	31
Eliquis	Apixaban	75	23
Escitalopram Oxalate	Escitalopram Oxalate	73	23
Omeprazole	Omeprazole	73	33
Donepezil Hcl	Donepezil Hcl	70	23
Duloxetine Hcl	Duloxetine Hcl	70	26
Metoprolol Succinate	Metoprolol Succinate	70	31
Hydrochlorothiazide	Hydrochlorothiazide	69	28
Finasteride	Finasteride	65	22
Albuterol Sulfate Hfa	Albuterol Sulfate	63	23
Rosuvastatin Calcium	Rosuvastatin Calcium	62	28
Memantine Hcl	Memantine Hcl	57	18
Hydrocortisone	Hydrocortisone	53	suppressed
Simvastatin	Simvastatin	53	14
Allopurinol	Allopurinol	51	14
Nifedipine Er	Nifedipine	51	25
Tramadol Hcl	Tramadol Hcl	44	19
Alendronate Sodium	Alendronate Sodium	43	12
Metoprolol Tartrate	Metoprolol Tartrate	43	16
Mirtazapine	Mirtazapine	43	13
Montelukast Sodium	Montelukast Sodium	40	suppressed
Trazodone Hcl	Trazodone Hcl	39	16
Furosemide	Furosemide	38	21
Enalapril Maleate	Enalapril Maleate	37	suppressed
Xarelto	Rivaroxaban	35	11
Potassium Chloride	Potassium Chloride	33	16
Pravastatin Sodium	Pravastatin Sodium	33	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	31	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	31	16
Clopidogrel	Clopidogrel Bisulfate	30	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	12
Citalopram Hbr	Citalopram Hydrobromide	29	suppressed
Januvia	Sitagliptin Phosphate	29	suppressed
Famotidine	Famotidine	28	12
Lidocaine	Lidocaine	27	suppressed
Pregabalin	Pregabalin	27	suppressed
Diclofenac Sodium	Diclofenac Sodium	26	suppressed
Chlorthalidone	Chlorthalidone	24	suppressed
Glipizide	Glipizide	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Spironolactone	Spironolactone	23	12
Valsartan	Valsartan	23	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	22	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	19	suppressed
Levetiracetam	Levetiracetam	19	suppressed
Glipizide Er	Glipizide	18	suppressed
Oxycodone Hcl	Oxycodone Hcl	18	11
Ozempic	Semaglutide	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	16
Isosorbide Dinitrate	Isosorbide Dinitrate	17	suppressed
Ursodiol	Ursodiol	17	suppressed
Vascepa	Icosapent Ethyl	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Bumetanide	Bumetanide	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Jardiance	Empagliflozin	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Prednisone	Prednisone	12	suppressed
Serevent Diskus	Salmeterol Xinafoate	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Lacosamide	Lacosamide	11	suppressed
Myrbetriq	Mirabegron	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error